Since the announcement of European Against Cancer (EAC) procedure for standardization and quality control of real-time quantitative PCR for minimal residual disease detection in leukemia (Gabert et al., 2003), we had followed this valuable protocol for the detection of several fusion transcripts including the BCR-ABL1 major (p210) transcript. This evidence concerns the gene ABL1 and leukemia.